Evaluation of response to intravenous corticosteroid treatment in graves' ophthalmopathy patients by clinical activity score
Main Article Content
Abstract
The objective was to evaluate the response to intravenous corticosteroid treatment in patients with active Graves' ophthalmopathy, based on the CAS score. The study was conducted on 13 patients receiving intravenous corticosteroid treatment from August 2022 to December 2023 at Hanoi Medical University Hospital. This was a clinical intervention study with no control group. Of 13 patients, the average age was 45.9 years old, the oldest patient being 64 years old and the youngest was 24 years old. Only 1 patient smoked. 8 patients were euthyroid. The patients’ condition was graded from very severe, severe to moderate. The average CAS score before treatment was 3.77. The average CAS score at week 6 of treatment decreased to 2.15; the difference was statistically significant with p < 0.05. The average CAS score at week 12 decreased further to 1.69, ; the difference was statistically significant with p < 0.05. The response rate after 12 weeks of treatment in our study was 84.6%.
Article Details
Keywords
Graves' Ophthalmopathy, Glucocorticoids, Clinical Activity Score
References
2. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid. 2002; 12(10): 855–860.
3. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016; 5(1): 9-26.
4. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021 Aug 27; 185(4): G43-G67. doi: 10.1530/EJE-21-0479.
5. Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011; 96(2): 320–332.
6. Ahn HY, Lee JK. Intravenous Glucocorticoid Treatment for Korean Graves’ Ophthalmopathy Patients. J Korean Med Sci. 2020 Jun 15; 35(23): e177. doi: 10.3346/jkms.2020.35.e177.
7. Aktaran S, Akarsu E, Erbağci I, Araz M, Okumuş S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2007; 61(1):45–51.
8. Kauppinen-Mäkelin R, Karma A, Leinonen E, Löyttyniemi E, Salonen O, Sane T, Setälä K, Viikari J, Heufelder A, Välimäki M. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand. 2002; 80(3):316–321.
9. Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G. High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J Endocrinol Invest. 2001; 24(3): 152–158.
10. Nguyễn Chiến Thắng. Nghiên cứu ứng dụng phẫu thuật giảm áp hốc mắt điều trị bệnh mắt Basedow mức độ nặng. Luận án tiến sĩ y học, trường đại học Y Hà Nội. 2014
11. Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab. 2007; 92:59–64.
12. Bahn R. S. Graves’ ophthalmopathy. The New England Journal of Medicine. 2010; 362(8): 726–738. doi: 10.1056/nejmra0905750.
13. Pérez-López M., Sales-Sanz M., Rebolleda G., et al. Retrobulbar ocular blood flow changes after orbital decompression in graves’ ophthalmopathy measured by color doppler imaging. Investigative Ophthalmology & Visual Science. 2011; 52(8): 5612–5617. doi: 10.1167/iovs.10-6907.
14. Lê Tiến Đạt, Nguyễn Thị Thanh Tú. Đặc điểm lâm sàng bệnh mắt do Basedow ở bệnh nhân khoa y học cổ truyền bệnh viện Nội tiết Trung Ương. Tạp chí Y học Việt Nam. 2022; 520 (2).
15. Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G. High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J Endocrinol Invest. 2001; 24(3):152–158.
16. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001; 86(8):3562–3567.
17. Zhu W., Ye L., Shen L., et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves’ ophthalmopathy. The Journal of Clinical Endocrinology & Metabolism. 2014; 99(6): 1999–2007.
18. He Y., Mu K., Liu R., Zhang J., Xiang N. Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves’ ophthalmopathy: a prospective, randomized controlled trial. Endocrine Journal. 2017; 64(2):141–149.
19. Young S. M., Lim A. Y. N., Lang S. S., Lee K. O., Sundar G. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease. Orbit. 2019; 38(5):362–369.
20. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995; 270: 286–290.